Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Diabetes Mellitus, Type 2
Phase NA
Enrollment 76
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to compare the effects of peer coaching models in older adults with unmanaged type two diabetes. The main questions it aims to answer are: * Are peer coaching models effective at promoting Type 2 Diabetes Mellitus self-management? * If effective, which facets of the peer model are most effective? Peer coaches will undergo peer coach training. * Reach out to peer participants on a weekly/biweekly time frame to discuss self-management and goal setting. Retain records of contact, topics discussed, and general notes on interactions. Researchers will compare differences in the frequency of contact, as well as how peer coaches were matched to peer participants to see if efficacy of the intervention is altered between groups.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Peer Coach Training - Weekly — Peer participants will be contacted by peer coaches on a weekly basis.
  • Behavioral: Peer Coach Training - Biweekly — Peer participants will be contacted by peer coaches on a bi-weekly basis

Primary Outcomes

  • Number of participants with change in A1c (Collected at Baseline, 6 months (at the end of the intervention), 3-months and 6-months post-intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-20
Completion: 2027-03-31
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: false
Enrollment: 76 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Medical Branch, Galveston
Collaborators: Department of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Brittany L. Smalls, PhD (PRINCIPAL_INVESTIGATOR) - University of Texas Medial Branch
Contact Information
Study Contact:
Brittany L. Smalls, PhD
409-772-1011
blsmalls@utmb.edu
Kindness C. Akwari, MS
502-627-0591
kcakwari@utmb.edu
Alecia Johnson
270-781-2381
alecia.johnson@bradd.org
Barren River Area Development District
Interventions
  • Behavioral: Peer Coach Training - Weekly — Peer participants will be contacted by peer coaches on a weekly basis.
  • Behavioral: Peer Coach Training - Biweekly — Peer participants will be contacted by peer coaches on a bi-weekly basis
Study Locations (2 sites)
Barren River Area Development District, Bowling Green, Kentucky 42101 United States
UK HealthCare, Hazard, Kentucky 41701 United States
Eligibility Criteria
Inclusion Criteria: * Age greater than or equal to 55 years * Resident in Rural Kentucky * Positive Diagnosis of Type 2 Diabetes Mellitus * HbA1c greater than or equal to 7.5% * Passing score on cognitive assessment administered by study personnel * English Speaking Exclusion Criteria: * Age less than 55 years * Not a resident of a Rural Kentucky County * No Type 2 Diabetes Mellitus Diagnosis * HbA1c under 7.5% * Cognitive Impairment * Non-english speaking
Conditions Preeclampsia, Maternal Deaths
Phase Not Applicable
Enrollment 50000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Preeclampsia is the main cause of illness and death in pregnant women and fetuses. Currently, there is no effective treatment for preeclampsia in clinical practice, and the fundamental treatment is still termination of pregnancy and placental delivery. Therefore, early prediction of preeclampsia and targeted strengthening of high-risk pregnant women supervision, early intervention and diagnosis and treatment can greatly reduce the serious obstetric complications and perinatal maternal and fetal deaths caused by preeclampsia, which has significant social and clinical significance.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Screening method — All pregnant women in the group were screened for pre-eclampsia risk according to the clinical risk factors listed in NICE Guidelines (2019).
  • Diagnostic Test: Screening method — In the first trimester, pregnant women with routine MAP and PLGF (with UtA-PI detection conditions plus UtA-PI) were tested, and the risk of preeclampsia was evaluated based on Bayes rule combined with maternal factors. In the second and third trimester of pregnancy, routine determination of PLGF or sFlt-1/PLGF was used to evaluate the risk of preeclampsia.

Primary Outcomes

  • Preeclampsia (42 days after delivery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-08-01
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 50000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Third Affiliated Hospital of Guangzhou Medical University
Principal Investigators:
  • Dunjin Chen, Professor (PRINCIPAL_INVESTIGATOR) - The Third Affiliated Hospital of Guangzhou Medical University
Contact Information
Study Contact:
Dunjin Chen, Professor
18928916722
gzdrchen@gzhmu.edu.cn
Fang He, M.D
13724831279
hefangjnu@126.com
FANG HE, M.D
13724831279
hefangjnu@126.com
FANG HE
Interventions
  • Diagnostic Test: Screening method — All pregnant women in the group were screened for pre-eclampsia risk according to the clinical risk factors listed in NICE Guidelines (2019).
  • Diagnostic Test: Screening method — In the first trimester, pregnant women with routine MAP and PLGF (with UtA-PI detection conditions plus UtA-PI) were tested, and the risk of preeclampsia was evaluated based on Bayes rule combined with maternal factors. In the second and third trimester of pregnancy, routine determination of PLGF or sFlt-1/PLGF was used to evaluate the risk of preeclampsia.
Study Locations (1 sites)
FANG HE, Guangzhou, Guangdong 510150 China
Eligibility Criteria
Inclusion Criteria: * 1\) Pregnant women who have been screened for pre-eclampsia risk according to the clinical risk factors listed in NICE guidelines (2019); * 2\) Based on the authoritative guideline of Figo and the consensus of experts in China, pregnant women who routinely use maternal factor +MAP+PLGF±UtA-PI in the first trimester or PLGF or sFlt-1/PLGF in the second and third trimesters to assess the risk of preeclampsia. * 3\) Meet any of the above conditions, join the group voluntarily, and sign the informed consent form. Exclusion Criteria: * 1\) Severe fetal malformation or abnormality (no fetal heartbeat); * 2\) Those who regularly use aspirin before joining the group; * 3\) There are obvious other abnormal signs, laboratory tests or other clinical d• iseases, which are judged by the researcher to be not suitable for participating in researchers; * 4\) Unable to obtain follow-up and delivery information.
Conditions Pre-Eclampsia, Pregnancy Induced Hyperte...
Phase Not Applicable
Enrollment 1100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To develop strategies to identify postpartum women at risk for adverse cardiovascular outcomes and provide them with preventative therapies.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Preeclampsia (2nd trimester - 13 months postpartum)
  • Gestational hypertension (2nd trimester - Delivery)
  • Postpartum hypertension (Delivery - 13 months postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-12-20
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 1100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Collaborators: National Human Genome Research Institute (NHGRI), Vanderbilt University Medical Center
Principal Investigators:
  • Louise Laurent, MD, PhD (PRINCIPAL_INVESTIGATOR) - UCSD
  • Marni Jacobs, PhD (PRINCIPAL_INVESTIGATOR) - UCSD
Contact Information
Study Contact:
Maya Selvaraj
858-249-5985
momhealthstudy@health.ucsd.edu
Valentina Stanley
858-249-5985
Maya Selvaraj
858-776-8374
mlselvaraj@health.ucsd.edu
University of California, San Diego
Interventions
N/A
Study Locations (1 sites)
University of California, San Diego, San Diego, California 92037 United States
Eligibility Criteria
Inclusion Criteria: * Pregnant women 18 years of age to 50 years of age * 10-24 weeks gestation at time of enrollment * Singleton pregnancy * Planning to deliver at a study site (UCSD or VUMC) Exclusion Criteria: * Inability to give informed consent * Intrauterine fetal demise * Fetal genetic or structural anomaly * Institutionalization for psychiatric disorder, mental deficiency or incarcerated * Active or history of malignancy requiring major surgery or systemic chemotherapy * Multi-fetal gestation or a twin demise at any gestational age * Known maternal or fetal chromosomal anomalies * Patients who plan to keep their placenta after delivery
Conditions Prehabilitation, Breast Cancer, Postmeno...
Phase NA
Enrollment 68
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer stands as the foremost cause of cancer-related deaths among women worldwide, with the highest incidence of any cancer type. The choice of therapeutic interventions hinges upon factors like cancer stage, cell subtype, and tumor size. Consequently, individuals with more aggressive tumors, such as HER+2 and Triple Negative, or larger tumors often undergo neoadjuvant chemotherapy before breast surgery. However, these anticancer treatments come with side effects like cancer-related fatigue, reduced functional capacity, and changes in body composition, notably skeletal muscle atrophy. Skeletal muscle loss correlates with heightened mortality rates, cardiotoxicity, and diminished quality of life, underscoring the need for early therapeutic interventions. One such promising strategy is prehabilitation, which involves resistance-exercise training aimed at bolstering skeletal muscle mass from the outset of the disease, even preceding breast surgery. Resistance-exercise training has shown favorable effects on women undergoing adjuvant therapy or survivors of breast cancer, however, its molecular and clinical effects in women with breast cancer undergoing neoadjuvant therapy are unknown.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Prehabilitation with resistance-exercise training — The volunteers in the intervention group will be subjected to 16 - 20 weeks of whole-body resistance-type exercise training (2x/wk).
  • Other: Usual care program — The volunteers in the intervention group will be subjected to usual care (diagnosis confirmation, chemotherapy treatment planning and an initial education session).

Primary Outcomes

  • Change in skeletal muscle mass (measured via Computed tomography (CT) scan) (Before training (week 0), and after training (up to 20 weeks) and 4 weeks post surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2026-12
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: true
Enrollment: 68 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universidad de La Frontera
Principal Investigators:
  • Gabriel N Marzuca-Nassr, PT, MSc, PhD (PRINCIPAL_INVESTIGATOR) - Universidad de La Frontera
Contact Information
Study Contact:
Macarena Artigas, PT, MSc
990420698
klga.macarena.artigas@gmail.com
Gabriel N Marzuca-Nassr, PT, MSc, PhD
+56 45 2596713
gabriel.marzuca@ufrontera.cl
Gabriel N Marzuca-Nassr, PT, MSc, PhD
+56 45 2596713
gabriel.marzuca@ufrontera.cl
Fundación Arturo López Pérez
Interventions
  • Other: Prehabilitation with resistance-exercise training — The volunteers in the intervention group will be subjected to 16 - 20 weeks of whole-body resistance-type exercise training (2x/wk).
  • Other: Usual care program — The volunteers in the intervention group will be subjected to usual care (diagnosis confirmation, chemotherapy treatment planning and an initial education session).
Study Locations (2 sites)
Fundación Arturo López Pérez, Santiago, Chile
Department of Rehabilitation Sciences, Faculty of Medicine, Universidad de La Frontera. Temuco, Chile, Temuco, Chile
Eligibility Criteria
Inclusion Criteria: * Postmenopausal women with breast cancer in stages I, II and III with luminal breast tumor, HER2+ or TNBC * Indication for neoadjuvant chemotherapy * Candidates for curative breast surgery * Body mass index: 18.5 \<BMI \<30 kg/m2 * Sedentary (does not perform scheduled or planned physical activity ≥ 2 times a week) * Willingness to participate in the study and follow the proposed prehabilitation scheme. Exclusion Criteria: * Present comorbidities that interact with the metabolism and mobility of the muscles of the body and that do not allow the (safe) performance of strength exercises (e.g., debilitating arthritis, all neurological disorders, paralysis, among others). * Severe or uncontrolled cardiovascular disease, cardiac ejection fraction less than 50% * Previous antineoplastic treatment * Use of nutritional supplements (leucine, glutamine, casein, whey protein, fatty acids and creatine).
Conditions Hypertensive Disorder of Pregnancy, Pre-...
Phase PHASE4
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and/or microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Triple

Interventions / Regimen

  • Drug: Low-dose aspirin — The intervention group will receive low-dose \[81 mg\] aspirin pill daily for 6 months.
  • Drug: Placebo — The control group will receive similar appearing placebo daily for 6 months.

Primary Outcomes

  • Percent of participants eligible, enrolled and retained (feasibility) (Baseline to approximately 6 months postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-05-29
Completion: 2027-10-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Malamo Countouris
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Alisse K Hauspurg, MD (PRINCIPAL_INVESTIGATOR) - UPMC Magee Women's Hospital
Contact Information
Study Contact:
Alisse K Hauspurg, MD
412-641-1381
janickia@upmc.edu
Sila Yavan, MS
4124174981
yavans@upmc.edu
Sila Yavan, MS
4124174981
yavans@upmc.edu
University of Pittsburgh Magee-Womens Hospital
Interventions
  • Drug: Low-dose aspirin — The intervention group will receive low-dose \[81 mg\] aspirin pill daily for 6 months.
  • Drug: Placebo — The control group will receive similar appearing placebo daily for 6 months.
Study Locations (1 sites)
University of Pittsburgh Magee-Womens Hospital, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria: * Postpartum individuals ≥18 years old * Preeclampsia diagnosis Exclusion Criteria: * Fetal anomaly * Multiple gestation * Pre-pregnancy hypertension * Allergy or contraindication to low-dose aspirin * Pre-pregnancy diabetes
Conditions Subthreshold Depression, Young People, T...
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess the mechanisms of the effect of transcranial direct current stimulation (tDCS) in alleviating subthreshold depressive symptoms in young individuals, and individualized outcome prediction is carried out.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Device: tdcs lDLPFC — The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3, cathode is on the FP2.
  • Device: tdcs rVLPFC — The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F6, cathode is on the FP1.
  • Device: Sham — The current only persist in the fisrt 30s, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3/F6, cathode is on the FP2/1.

Primary Outcomes

  • The effect of tDCS in alleviating subthreshold depressive symptoms (2 weeks, 1 month and 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-01
Completion: 2025-12
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: true
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guangzhou Psychiatric Hospital
Principal Investigators:
  • Kangguang Lin, M.D;PH.D (STUDY_DIRECTOR) - The Affiliated Brain Hospital of Guangzhou Medical University
  • Robin Shao, Ph.D (PRINCIPAL_INVESTIGATOR) - The Affiliated Brain Hospital of Guangzhou Medical University
Contact Information
Study Contact:
Kangguang Lin, M.D;Ph.D
86-02081268189
linkangguang@163.com
Kangguang Lin, M.D;Ph.D
86-13560360144
klin@gzhmu.edu.cn
Guangzhou Brain hospital(Guangzhou Huiai Hospital)
Interventions
  • Device: tdcs lDLPFC — The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3, cathode is on the FP2.
  • Device: tdcs rVLPFC — The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F6, cathode is on the FP1.
  • Device: Sham — The current only persist in the fisrt 30s, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3/F6, cathode is on the FP2/1.
Study Locations (1 sites)
Guangzhou Brain hospital(Guangzhou Huiai Hospital), Guangzhou, Guangdong 510370 China
Eligibility Criteria
Inclusion Criteria: * 1\) Be between the ages of 12-25; * 2\) is right-handed on the Edinburgh Handedness Inventory; * 3\) 2-4 of the 9 depressive symptoms defined by the American Diagnostic and Statistical Manual of Diseases, Fifth Edition (DSM-5), lasting more than 1 week; or more than 5 depressive symptoms lasting more than 1 week but less than 2 weeks (i.e., not meeting criteria for a major depressive episode) (by DSM-5 Clinical Semi-Definitive Interview (K-SADS-PL) (Gilbody et al., 2017, JAMA); * 4\) Hamilton Depression Scale (HAMD-24) 24 points≥ 8 points, \&lt; 24 points; * 5\) Gender is not limited; * 6\) Subjects and their families voluntarily participate and sign the informed consent form. Exclusion Criteria: * 1\) Individuals with the following diagnoses according to DSM-5: psychiatric disorders due to organic diseases, substance-related and addictive disorders, neurodevelopmental disorders, schizophrenia spectrum and other psychotic disorders, bipolar disorder (assessed by K-SADS-PL); * 2\) Have two or more DSM-V-defined manic symptoms for 4 days but do not meet the criteria for hypomania or meet the DSM-V defined criteria for hypomanic symptoms for only 2-3 days; * 3\) Severe or unstable physical illness; * 4\) have a moderate or higher risk of suicide (as assessed by the Columbia Suicide Severity Scale); * 5\) Received transcranial direct current stimulation in the past three months (continuous intervention time: \&gt;2 weeks); * 6\) Contraindications to transcranial direct current stimulation, such as brain implants, personal or family history of epilepsy; * 7\) Magnetic resonance scanning is contraindicated, such as in vivo metal implants.
Conditions Depression
Phase EARLY_PHASE1
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to compare the efficacy of two related, but different ABM (Attention Biased Modification) treatments for depression in adults with elevated symptoms of depression. The main aims are: * Aim 1:examine whether gamified ABM leads to greater change in the primary and secondary outcomes than sham ABM * Aim 1: establish that gamified ABM is at least as effective as traditional ABM. * Aim 2: identify moderators of ABM efficacy and mechanisms responsible for its efficacy. * Aim 3: Identify the durability of ABM on depression symptoms during short-term follow-up Participants will complete self-report questionnaires, complete eye-tracking tasks, and be clinically assessed through interviews by clinician researchers. If there is a comparison group: Researchers will compare sham, traditional, and gamified treatment groups to see if they moderate symptoms of depression.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Behavioral: Traditional Attention Bias Modification — Each ABM trial begins with a central fixation cross for 1500ms, followed by a pair of POFA or IAPS stimuli (see Figure 3). POFA pairs will be presented for 3000ms, while IAPS pairs will be presented for 4500ms (due to the increased image complexity of IAPS images relative to POFA images). Longer stimulus duration times were selected based on evidence that attention biases for sad stimuli are prolonged in depression. Following offset of the images, either a single or double asterisk probe appears in the location of one of the images and will remain until a participant response or 10,000ms. In active ABM, the probe had an 80% probability of appearing in the location of the neutral stimulus. Investigators selected 80% rather than 100% to allow for computing attention bias during training and to facilitate task engagement. At the end of each ABM session, participants are provided feedback regarding their task performance relative to their last five sessions in a visual format.
  • Behavioral: Gamified Attention Bias Modification — Each trial consists of the fixation stage, facial cue stage, and response stage. At the fixation stage, an image appears (a colorful medallion) for 500 ms. The fixation appears randomly within a fixed rectangular field on the user's smartphone screen, and is always at the midpoint between the two face cues that will appear in the next stage. Next, after the cue disappears, two animated faces appear on the screen, one happy and one sad, with a 1000ms duration. Immediately after they disappear, a target probe (a trail) appears in the location of the happy face cue. The path remains (up to 3 seconds) until participants respond by tracing it starting from the point at which the face cue disappeared. They are instructed to quickly but accurately trace the path with their finger and receive visual and haptic feedback during tracing to indicate they are tracing accurately, followed by the path disappearing.
  • Behavioral: Sham Attention Bias Modification — Sham attention bias modification designed to match the active ABM condition in all respects except for the shifting attention away from negative stimuli in active attention bias modification.

Primary Outcomes

  • QIDS (Quick Inventory of Depression Symptoms) SR-16 (Screening, Baseline, Weeks 1-4 (Acute Period), Weeks 12-28 (Follow-Up Period))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2024-05-01
Completion: 2028-05-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas at Austin
Collaborators: Arcade Therapeutics
Principal Investigators:
  • Christopher G Beevers, PhD (PRINCIPAL_INVESTIGATOR) - UT Austin
Contact Information
Study Contact:
Christopher G Beevers, PhD
5124717557
beevers@utexas.edu
Christopher G Beevers, PhD
beevers@utexas.edu
Institute for Mental Health Research
beevers@utexas.edu
Institute for Mental Health Research
Interventions
  • Behavioral: Traditional Attention Bias Modification — Each ABM trial begins with a central fixation cross for 1500ms, followed by a pair of POFA or IAPS stimuli (see Figure 3). POFA pairs will be presented for 3000ms, while IAPS pairs will be presented for 4500ms (due to the increased image complexity of IAPS images relative to POFA images). Longer stimulus duration times were selected based on evidence that attention biases for sad stimuli are prolonged in depression. Following offset of the images, either a single or double asterisk probe appears in the location of one of the images and will remain until a participant response or 10,000ms. In active ABM, the probe had an 80% probability of appearing in the location of the neutral stimulus. Investigators selected 80% rather than 100% to allow for computing attention bias during training and to facilitate task engagement. At the end of each ABM session, participants are provided feedback regarding their task performance relative to their last five sessions in a visual format.
  • Behavioral: Gamified Attention Bias Modification — Each trial consists of the fixation stage, facial cue stage, and response stage. At the fixation stage, an image appears (a colorful medallion) for 500 ms. The fixation appears randomly within a fixed rectangular field on the user's smartphone screen, and is always at the midpoint between the two face cues that will appear in the next stage. Next, after the cue disappears, two animated faces appear on the screen, one happy and one sad, with a 1000ms duration. Immediately after they disappear, a target probe (a trail) appears in the location of the happy face cue. The path remains (up to 3 seconds) until participants respond by tracing it starting from the point at which the face cue disappeared. They are instructed to quickly but accurately trace the path with their finger and receive visual and haptic feedback during tracing to indicate they are tracing accurately, followed by the path disappearing.
  • Behavioral: Sham Attention Bias Modification — Sham attention bias modification designed to match the active ABM condition in all respects except for the shifting attention away from negative stimuli in active attention bias modification.
Study Locations (1 sites)
Institute for Mental Health Research, Austin, Texas 78705 United States
Eligibility Criteria
Inclusion Criteria: * Provided informed consent * Fluent in English * Scored 13 or greater on the QIDS-SR at the baseline assessment * Between the ages of 18 to 70 * Have had no changes in medication and dosage in the past 12 weeks (if currently on antidepressant medication) Exclusion Criteria: * Reported suicidal behavior or significant suicidal ideation within the past six months using the Columbia-Suicide Severity Rating Scale (C-SSRS) * Met criteria for current or past bipolar or psychotic disorders * Current (i.e., within the past 12 months) substance use disorders of moderate or greater severity on the Mini International Neuropsychiatric Interview (MINI) * Currently taking opioid analgesics or systemic corticosteroid use as these medications * Currently receiving psychotherapy
Conditions Breast Cancer
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Some types of localised breast cancer, including stage II and III, HER2 positive (Human Epidermal Growth Factor Receptor) or triple negative cancers are treated with primary or neoadjuvant chemotherapy prior to surgical treatment (mastectomy or conservative treatment). Follow-up with neoadjuvant or primary chemotherapy is usually done by breast Magnetic Resonance Imaging (MRI).Tumour response to treatment is assessed on morphological size criteria. Angiomammography (also called CESM : Contrast Enhanced Spectral Mammography) is an innovative and validated imaging technique consisting of dual energy mammography with injection of iodinated contrast medium; two images are generated, one comparable to a standard mammography and a second image highlighting the structures enhanced by the contrast medium. The characteristic neo angiogenesis of the tumour process thus allows good visualisation of the tumour compared to the underlying mammary gland. A classical morphological analysis is therefore possible thanks to standard mammographic acquisition coupled with a quantitative functional analysis linked to the study of enhancement. During angiomammography, several images are acquired in succession, starting with the cranio caudal view and ending with the profile view. On the same examination, these acquisitions are carried out at different injection times, making it possible to study the type of enhancement of a given area (Progressive/ Plateau/ Wash out). Angiomammography has several advantages over breast MRI in the follow-up of chemotherapy: shorter examination time, shorter appointment time, better tolerated by the patients and without injection of Gadolinium chelates, which have recently been shown to cause definitive brain deposits during repeated injections. Currently, angiomammography is validated in the follow-up of breast cancers treated with neoadjuvant or primary chemotherapy, with an analysis of tumour response currently only morphological, as in breast MRI. Here, the hypothesis is that the study of tumour enhancement by angiomammography may constitute a new predictive element of histological response: indeed, the performance of an initial angiomammography before treatment (baseline) and then a second angiomammography performed early in relation to the start of chemotherapy, could allow early prediction of which patients will have a complete histological response at the time of the closing surgery. This prospective study is to compare the variation in tumour enhancement, assessed on each of the two examinations using dedicated X-ray consoles, to the final histological result after closure surgery: it is hoped that the relative variation in tumour enhancement would be greater in responding patients.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Diagnostic test — * Inclusion visit (V1) Initial baseline CESM (V2) 15 days after inclusion * First chemotherapy treatment (V3) 28 days after V2. * Unilateral follow-up CESM (V4) 4 to 6 weeks after the first course of chemotherapy. * Surgery (V5): 3 to 6 weeks later at the end of the complete treatment with primary chemotherapy * End of research visit (V6) It corresponds to the histological analysis on the surgical specimen after the complete treatment with neoadjuvant or primary chemotherapy.

Primary Outcomes

  • The evolution of the relative tumor enhancement (RTEe) (%) between the baseline and early re-evaluation CESM (At baseline, 2 and 8 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-23
Completion: 2027-05
Eligibility
Age: 35 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospices Civils de Lyon
Contact Information
Study Contact:
Dorothée TACONET, MD
0426109185
dorothee.taconet@chu-lyon.fr
Dorothée TACONET, MD
0426109185
dorothee.taconet@chu-lyon.fr
Hôpital de la Croix Rousse
Interventions
  • Diagnostic Test: Diagnostic test — * Inclusion visit (V1) Initial baseline CESM (V2) 15 days after inclusion * First chemotherapy treatment (V3) 28 days after V2. * Unilateral follow-up CESM (V4) 4 to 6 weeks after the first course of chemotherapy. * Surgery (V5): 3 to 6 weeks later at the end of the complete treatment with primary chemotherapy * End of research visit (V6) It corresponds to the histological analysis on the surgical specimen after the complete treatment with neoadjuvant or primary chemotherapy.
Study Locations (1 sites)
Hôpital de la Croix Rousse, Lyon, 69004 France
Eligibility Criteria
Inclusion Criteria: * With a histological diagnosis of stage II or III localised breast cancer, with an indication for first or neoadjuvant chemotherapy validated by the RCP: HER2+, Triple negative * Affiliated or beneficiary of a social security scheme or similar * Having signed an informed consent for participation in the study. Exclusion Criteria: * Patients considered to be at very high risk (BRCA 1 and 2 mutation, Li Fraumeni syndrome, Lynch syndrome, previous thoracic irradiation for lymphoma) and high genetic risk as determined by an oncogenetic consultation * Pregnancy, breastfeeding * Contraindication to the injection of iodinated contrast material: hypersensitivity to the active substance or to one of the excipients of the contrast material, renal insufficiency with glomerular filtration rate \< 35ml/min * Patients who do not master the French language * Patient who is an adult protected by law, under curatorship or guardianship * Patient who has participated in another research study with a current exclusion period
Conditions Insomnia, Insomnia Chronic, Insomnia, Pr...
Phase EARLY_PHASE1
Enrollment 600
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Individuals who have insomnia with short sleep duration (ISS) differ from individuals who have insomnia with normal sleep duration (INS) in terms of health risks (i.e., hypertension) and treatment response. This study will examine whether patients with ISS and INS demonstrate a differential response to two common insomnia treatments. One is behavioral, Cognitive Behavioral Therapy for Insomnia (CBT-I). The other is a widely prescribed, non-habit-forming medication, trazodone used at a low dose. The investigators' findings could lead to evidence-based treatment guidelines that help clinicians more effectively match treatments to insomnia patients and reduce associated health problems.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: Cognitive Behavioral Treatment for Insomnia (CBT-I) — Subjects will receive therapy for 8 weeks
  • Drug: Trazodone — Non-remitting subjects will receive Trazodone (dosage) for 8 weeks
  • Other: Placebo — Non-remitting subjects will receive placebo for 8 weeks

Primary Outcomes

  • Remission of insomnia symptoms following Cognitive Behavioral Therapy for Insomnia (CBT-I) (9 weeks)
  • Remission of insomnia symptoms following trazodone/placebo Randomized Controlled Trial (RCT) (9 weeks)
  • Remission of insomnia symptoms 6 months following completion of CBT-I Or RCT Treatment (35 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2024-03-20
Completion: 2028-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Milton S. Hershey Medical Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Alexandros Vgontzas, MD (PRINCIPAL_INVESTIGATOR) - Professor, Psychiatry
Contact Information
Study Contact:
Carrie Criley
717-531-4123
ccriley@pennstatehealth.psu.edu
Roxane Horberg
303-270-2850
horbergr@njhealth.org
National Jewish Health
Rachel Johnson
303 398-1058
johnsonr@njhealth.org
National Jewish Health
Interventions
  • Behavioral: Cognitive Behavioral Treatment for Insomnia (CBT-I) — Subjects will receive therapy for 8 weeks
  • Drug: Trazodone — Non-remitting subjects will receive Trazodone (dosage) for 8 weeks
  • Other: Placebo — Non-remitting subjects will receive placebo for 8 weeks
Study Locations (4 sites)
National Jewish Health, Denver, Colorado 80206-2761 United States
Penn State University, Hershey, Pennsylvania 17033 United States
University of Pittsburgh, Pittsburgh, Pennsylvania 15213-3203 United States
Université Laval, Québec, Quebec G1V 0A6 Canada
Eligibility Criteria
Inclusion Criteria: * Age 18 or older * Able to read and effectively communicate in English at the United States sites or able to read and effectively communicate in English or French at the Canadian site. * Meets criteria for chronic insomnia * Body Mass Index (BMI) 18.5 kg/m2 and higher Exclusion Criteria: * Age \< 18 * Unable to read and effectively communicate in English at the United States sites or able to read and effectively communicate in English or French at the Canadian site. * Unwilling to share email address/cell phone number to accept survey links. * Life time diagnosis of psychotic or bipolar disorder * History of severe apnea or an Apnea Hypopnea Index (AHI) ≥15 that is not currently treated with Positive Airway Pressure (PAP) therapy, an oral device or an implanted device, or was not treated with surgery or weight loss. * Started new or changed treatment for sleep apnea in the past three months * Does not meet criteria for chronic insomnia * Meets criteria for narcolepsy or hypersomnia disorder * Meets criteria for circadian rhythm disorder (including night shift work) * Unstable medical conditions that would make participation unsafe or unfeasible * Falls resulting in hospitalization, significant injury or fracture within past 12 months * 2 hospitalizations or emergency room visits within past 12 months for chronic conditions * Active chemotherapy or radiation therapy for cancer * Lifetime diagnoses/treatment of chronic renal failure, hepatic insufficiency, chronic heart failure * Does not agree to refrain from other treatments for insomnia beyond what is offered in this study * BMI less than 18.5 * Substance abuse or dependence in the past 12 months * Current use of prescription or over the counter medications taken for sleep greater than 2 times per week * Current use of systemic corticosteroids or opiate medications * Current pregnancy or breastfeeding; plans to get pregnant or unwillingness to use birth control for the length of the study * Current use of medications contraindicated with trazodone * Sleep apnea or periodic leg movement disorder as determined by sleep study * Blood Pressure levels defined as seated SBP greater than 180 or DBP greater than 110 mmHg * EKG corrected QT interval greater than or equal to 500 ms
Conditions Metastatic Breast Cancer
Phase PHASE3
Enrollment 378
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ESG401 — IV infusion on day 1,8, and 15 of each 28 day cycle
  • Drug: Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice) — Eribulin, capecitabine, gemcitabine or vinorelbine

Primary Outcomes

  • Progression-free survival (PFS) assessed by IRC per RECIST 1.1 (Up to 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-07-11
Completion: 2028-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 378 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Qilu Pharmaceutical Co., Ltd.
Principal Investigators:
  • Fei Ma, PhD (PRINCIPAL_INVESTIGATOR) - Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Yong Yuan, Master Degree
+86 13820384005
yong3.yuan@qilu-pharma.com
Fei Ma, PhD
Cancer Hospital Chinese Academy of Medical Sciences
Interventions
  • Drug: ESG401 — IV infusion on day 1,8, and 15 of each 28 day cycle
  • Drug: Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice) — Eribulin, capecitabine, gemcitabine or vinorelbine
Study Locations (1 sites)
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Inclusion Criteria: * Individuals able to understand and give written informed consent. * Males or females aged ≥ 18 years ; * Histologically and/or cytologically confirmed HR+/HER2- breast cancer who had failed at least one line of systemic chemotherapy in metastatic settings; * Patients who are eligible for a chemotherapy regimen in the control group; * Patients with at least one measurable lesion per RECIST 1.1 criteria; * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1; * Expected survival ≥ 12 weeks; * Patients with adequate organ and bone marrow function; * Female patients of childbearing potential and male patients with partners of childbearing potential who use effective medical contraception from the time of signing the informed consent form until 180 days after the last dose. Exclusion Criteria: * Received chemotherapy, targeted therapy, immunotherapy, interventional therapy or other systemic anti-cancer therapie within 4 weeks before the first investigational product administration; * Toxicities from prior anti-tumor therapy not recovering to ≤ Grade 1; * Received major surgeries 4 weeks prior to the first dose of study treatment or planned to receive major surgeries during the study ; * Prior topoisomerase I inhibitor therapy, including antibody-drugconjugate(ADC) therapy, or prior TROP2 targeted therapy, or use of any investigational anti-cancer drug within 28 days or 5 half-lives before the first investigational product administration; * New thromboembolic events, intestinal obstruction, gastrointestinal bleeding or perforation within 6 months; * Uncontrolled systemic bacterial, viral or fungal infections; * Subjects with symptomatic or untreated CNS metastases, or those requiring ongoing treatment for CNS metastases; * Patients with Primary CNS malignancy;or patients with other malignancies within 3 years prior to the first dose; * Patients with uncontrollable systemic diseases; * Patients with gastrointestinal diseases (such as chronic gastritis, chronic enteritis or gastric ulcers), or with a previous history of severe or chronic diarrhea; * Subjects with clinically significant cardiovascular disease; * Human Immunodeficiency Virus (HIV) infection; * Active hepatitis B or hepatitis C; * Known immediate or delayed hypersensitivity reaction to irinotecan or other camptocampin derivatives such as topotecan or to have had grade ≥3 gastrointestinal reactions associated with irinotecan, or allergies, or to any investigational drug or excipient ingredient; * Pregnant or lactating women.
Conditions Breast Cancer, Gynecologic Cancer
Phase NA
Enrollment 285
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Psychological distress is common among Vietnamese cancer patients but often underestimated and not detected by professionals due to lack of time and overload of clinical work. Currently no established, evidence-based intervention exists to help address the mental health needs of cancer patients in Viet Nam besides the 'Stronger Together' peer mentoring intervention model that the investigators piloted in 2021-2023. The goal of this 2-arm, parallel, single-blind randomized controlled trial (RCT) is to pilot and evaluate the Vietnamese Self Help Plus (vSH+) stress management intervention among breast and gynecologic cancer patients in Viet Nam. Aim 1- the investigators pilot the adapted vSH+ intervention. After recruitment and screening, participants are randomized into either the intervention (vSH+) or enhanced usual care (EUC) study arms. Participants are invited to attend an in-person informational session (IS) specific to their study arm, where informed consent is obtained. Aim 2- the investigators assess the potential effectiveness of the vSH+ intervention. Quantitative surveys of study outcomes measures are administered at three timepoints: T0 (baseline, in-person, during info-sessions); T1 (1-2 weeks post-intervention, via phone); and T2 (3 months post-intervention, via phone). Aim 3- the investigators conduct a qualitative process evaluation, via in-depth interview (IDIs) and focus group discussions (FGDs), to assess the acceptability and feasibility implementing and scaling up the vSH+ intervention model. Satisfaction surveys will be administered during vSH+ sessions and in-depth interviews (IDIs) will be conducted following the conclusion of the intervention. IDIs wil also be conducted with Facilitators, in addition to evaluation surveys during vSH+ sessions and supportive supervision sessions. Between T1 and T2, the investigators will conduct IDIs with Healthcare Workers and focus group discussions with Caregivers.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Vietnamese Self-Help Plus (vSH+) — vSH+ is a stress management program delivered through four 75-minute sessions. It includes the five core SH+ skills. Healthcare workers (nurses and social workers) function as lead facilitators (called 'HW Facilitators') and cancer survivors as co-facilitators (called 'Peer Facilitators').
  • Other: 'Doing What Matters in Times of Stress' (DWM) Guide — An illustrated guide developed by WHO to equip people with practical skills to help cope with stress which has been translated to Vietnamese and reviewed and revised by the investigators.

Primary Outcomes

  • Change in severity of depression (Baseline, 1 month, 3 months)
  • Change in Anxiety (Baseline, 1 month, 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-05
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 285 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Boston University
Collaborators: Fogarty International Center of the National Institute of Health
Principal Investigators:
  • Phuongthao Le, PhD (PRINCIPAL_INVESTIGATOR) - Boston University
Contact Information
Study Contact:
Phuongthao Le, PhD
617 358 1342
ptle@bu.edu
Interventions
  • Behavioral: Vietnamese Self-Help Plus (vSH+) — vSH+ is a stress management program delivered through four 75-minute sessions. It includes the five core SH+ skills. Healthcare workers (nurses and social workers) function as lead facilitators (called 'HW Facilitators') and cancer survivors as co-facilitators (called 'Peer Facilitators').
  • Other: 'Doing What Matters in Times of Stress' (DWM) Guide — An illustrated guide developed by WHO to equip people with practical skills to help cope with stress which has been translated to Vietnamese and reviewed and revised by the investigators.
Study Locations (6 sites)
Can Tho Oncology Hospital, Can Tho, Vietnam
Oncology Center, Cho Ray Hospital, Chợ Rây, Vietnam
Da Nang Oncology Hospital, Da Nang, Vietnam
Breast and Gynecology Department, Hung Vuong Women's Hospital, Ho Chi Minh City, Vietnam
Ho Chi Minh City Oncology Hospital, Ho Chi Minh City, Vietnam
Oncology Center, Hue Central Hospital, Huế, Vietnam
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or older * Have a clinician-confirmed diagnosis within the past 12 months of first-time breast and/or gynecologic cancer (e.g., cervical, ovarian, uterine, vaginal, vulvar) in stages I-III * Currently or will receive treatment with curative intent * Score less than 8 on the National Comprehensive Cancer Network (NCCN) Distress Thermometer, indicating low to moderate levels of distress * Score less than 15 on the Patient Health Questionnaire-9 items (PHQ-9, indicating low to moderate levels of depression Exclusion Criteria: * Selected '2 Several days' or '3 Almost everyday' on PHQ9 item #9, indicating indicating imminent risk of suicide * Have severe chronic diseases (e.g., coronary heart disease, chronic obstructive pulmonary disease (COPD), chronic renal failure), at the discretion of the treating clinician or study investigator * People with a risk for psychosis, mania, and alcohol abuse, based on screening questions commonly used in the field * Cannot attend the intervention activities at the hospital during the proposed intervention period
Conditions Hypertension, Target Organ Damage, Heart...
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of the GlycOxiTOD observational registry is to improve the early detection and characterization of vascular and other target-organ damage in adults at increased cardiovascular risk. Target-organ damage (TOD) means changes in the arteries, heart, kidneys, or other organs that may develop before cardiovascular symptoms or events occur. The registry studies how blood pressure, arterial function, vascular imaging, metabolic and glycoxidative markers, and non-invasive optical signals are related to this early damage. The main questions are: * Which clinical, blood pressure, imaging, and laboratory markers are associated with vascular and other target-organ damage? * Can photoplethysmography, a non-invasive optical technique that records changes in blood flow, identify abnormal arterial features? * Are new devices, measurement procedures, and signal-analysis methods technically valid, reliable, and reproducible when compared with established clinical methods? * Can combinations of clinical, imaging, laboratory, and device-derived measurements improve cardiovascular risk assessment? * How do vascular abnormalities and target-organ damage change during follow-up? Researchers will not assign any treatment as part of this observational registry. Participants will receive assessments that may include: * Clinical and cardiovascular risk evaluation * Office and 24-hour ambulatory blood pressure measurements * Blood and urine tests for metabolic, glycation, oxidative stress, and inflammatory markers * Non-invasive vascular ultrasound and arterial function measurements * Optical photoplethysmography recordings from peripheral or cervical arterial sites * Skin measurement of advanced glycation end products * Retinal imaging, when available * Repeated measurements to assess the reliability and reproducibility of selected devices and procedures * Follow-up using clinical visits and medical records to identify changes in target-organ damage and cardiovascular events The registry provides a shared clinical research platform for studies on hypertension, vascular imaging, arterial biomechanics, biomarkers, optical technologies, and the technical and methodological validation of non-invasive cardiovascular devices. Its overall aim is to support the development of reliable tools for early cardiovascular risk assessment and prevention.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Diagnostic Test: Multimodal Cardiovascular Phenotyping — Multimodal cardiovascular phenotyping may include clinical and anthropometric assessment; office and 24-hour ambulatory blood pressure monitoring; vascular ultrasound and arterial-function measurements; blood and urine biomarkers related to metabolism, glycation, oxidative stress, and inflammation; skin advanced glycation assessment; retinal imaging; and peripheral or cervical photoplethysmography. Selected measurements may be repeated to assess technical feasibility, agreement with reference methods, repeatability, reproducibility, and signal or image quality of non-invasive devices and analytical procedures. Assessments depend on the applicable protocol or nested study, and not all participants undergo every procedure.

Primary Outcomes

  • Presence of Baseline Vascular Target-Organ Damage or Subclinical Vascular Disease (At the baseline vascular assessment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-10
Completion: 2035-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Complejo Hospitalario Universitario de Santiago
Collaborators: Sociedad Española De Medicina Interna, Axencia Galega de Innovación (GAIN), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)
Contact Information
Study Contact:
Nestor Vazquez-Agra, PhD
0034981951256
nestor.vazquez.agra@sergas.es
Nestor Vazquez Agra, PhD
0034981951256
nestor.vazquez.agra@sergas.es
Complejo Hospitalario Universitario de Santiago de Compostela
Nestor Vazquez-Agra, PhD
Complejo Hospitalario Universitario de Santiago de Compostela
Interventions
  • Diagnostic Test: Multimodal Cardiovascular Phenotyping — Multimodal cardiovascular phenotyping may include clinical and anthropometric assessment; office and 24-hour ambulatory blood pressure monitoring; vascular ultrasound and arterial-function measurements; blood and urine biomarkers related to metabolism, glycation, oxidative stress, and inflammation; skin advanced glycation assessment; retinal imaging; and peripheral or cervical photoplethysmography. Selected measurements may be repeated to assess technical feasibility, agreement with reference methods, repeatability, reproducibility, and signal or image quality of non-invasive devices and analytical procedures. Assessments depend on the applicable protocol or nested study, and not all participants undergo every procedure.
Study Locations (1 sites)
Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña 15706 Spain
Eligibility Criteria
INCLUSION CRITERIA * Age 18 years or older. * Written informed consent to participate in the registry. * Undergoing cardiovascular risk or hypertension assessment in a primary-prevention setting. * At least one of the following cardiovascular risk conditions: * Confirmed hypertension requiring specialist cardiovascular assessment. * A SCORE2 estimated 10-year cardiovascular risk of 2% or higher in participants aged 40 to 69 years, when SCORE2 is applicable. * A SCORE2-OP estimated 10-year cardiovascular risk of 2% or higher in participants aged 70 to 89 years, when SCORE2-OP is applicable. * Type 2 diabetes with at least moderate cardiovascular risk according to SCORE2-Diabetes in participants within its validated age range, or according to guideline-defined clinical risk criteria when SCORE2-Diabetes is not applicable. * Chronic kidney disease confirmed for at least 3 months, defined by an estimated glomerular filtration rate below 60 mL/min/1.73 m², a urinary albumin-to-creatinine ratio of 30 mg/g or higher, or another persistent marker of kidney damage. * Hypertension-mediated target-organ damage or subclinical atherosclerotic vascular disease documented by clinical, laboratory, imaging, or functional assessment. * Confirmed or probable familial hypercholesterolemia. * For participants aged 18 to 39 years or older than 89 years, a documented major cardiovascular risk condition, such as hypertension, type 2 diabetes, chronic kidney disease, familial hypercholesterolemia, or target-organ damage. EXCLUSION CRITERIA * Inability or unwillingness to provide written informed consent. * Established clinical cardiovascular disease requiring secondary-prevention management, including previous myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack, coronary or peripheral revascularization, symptomatic peripheral artery disease, or other established symptomatic cardiovascular disease. * Acute or clinically unstable illness that prevents completion of the baseline registry assessment. * A medical, technical, cognitive, or logistical condition that prevents completion of the minimum required registry procedures.